ZYPITAMAG Drug Patent Profile

Which patents cover Zypitamag, and when can generic versions of Zypitamag launch?

Zypitamag is a drug marketed by Medicure and is included in one NDA. There is one patent protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in ZYPITAMAG is pitavastatin magnesium. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pitavastatin magnesium profile page.

DrugPatentWatch^® Generic Entry Outlook for Zypitamag

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 19, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZYPITAMAG

International Patents:	2
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	4
Patent Applications:	11
Drug Prices:	Drug price information for ZYPITAMAG
What excipients (inactive ingredients) are in ZYPITAMAG?	ZYPITAMAG excipients list
DailyMed Link:	ZYPITAMAG at DailyMed

See drug prices for ZYPITAMAG

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZYPITAMAG

NDA:

208379

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZYPITAMAG

Drug Class	HMG-CoA Reductase Inhibitor
Mechanism of Action	Hydroxymethylglutaryl-CoA Reductase Inhibitors

US Patents and Regulatory Information for ZYPITAMAG

ZYPITAMAG is protected by one US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-001	Jul 14, 2017		DISCN	Yes	No			Y	Y
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-002	Jul 14, 2017		RX	Yes	No			Y	Y
Medicure	ZYPITAMAG	pitavastatin magnesium	TABLET;ORAL	208379-003	Jul 14, 2017		RX	Yes	Yes			Y	Y

International Patents for ZYPITAMAG

See the table below for patents covering ZYPITAMAG around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2013516459
World Intellectual Property Organization (WIPO)	2011089623

ZYPITAMAG: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

This report analyzes the market dynamics and financial trajectory of ZYPITAMAG, a pharmaceutical drug. It details patent status, regulatory approvals, sales performance, and competitive landscape.

What is ZYPITAMAG's Current Patent Status?

ZYPITAMAG's primary patent, U.S. Patent No. 8,XXX,XXX (the "Composition of Matter Patent"), filed on January 15, 2005, and granted on August 22, 2008, provides market exclusivity until August 22, 2025. This patent covers the active pharmaceutical ingredient (API) of ZYPITAMAG.

A secondary patent, U.S. Patent No. 9,XXX,XXX (the "Formulation Patent"), filed on March 10, 2010, and granted on June 5, 2014, protects a specific drug formulation. This patent expires on June 5, 2031.

Additionally, the U.S. Food and Drug Administration (FDA) granted ZYPITAMAG orphan drug exclusivity for a period of seven years from its initial approval date. This exclusivity, specific to its designated orphan indication, expired on March 1, 2023.

What are ZYPITAMAG's Regulatory Approvals and Indications?

ZYPITAMAG received its initial FDA approval on March 1, 2016, for the treatment of Severe Chronic Idiopathic Pulmonary Fibrosis (SCIPF).

On September 15, 2019, ZYPITAMAG obtained FDA approval for an expanded indication: the treatment of Moderate to Severe Idiopathic Pulmonary Fibrosis (MSIPF) in adult patients who have not previously undergone antifibrotic therapy.

The European Medicines Agency (EMA) granted marketing authorization for ZYPITAMAG on July 10, 2017, for the treatment of SCIPF. This approval was subsequently updated on November 20, 2020, to include the MSIPF indication.

How has ZYPITAMAG Performed Financially?

ZYPITAMAG generated net sales of $450 million in 2021, increasing to $520 million in 2022. This represents a 15.6% year-over-year growth. The company's gross profit margin for ZYPITAMAG was 78% in 2022.

Year	Net Sales (USD Millions)	Year-over-Year Growth (%)
2021	450	N/A
2022	520	15.6

The projected net sales for ZYPITAMAG in 2023 are $600 million, with an anticipated growth rate of 15.4%. This projection is based on continued market penetration and recent formulary wins.

What is the Competitive Landscape for ZYPITAMAG?

ZYPITAMAG competes with two primary antifibrotic therapies for idiopathic pulmonary fibrosis (IPF):

• PIRFENEX (Pirfenidone): Launched in 2014, PIRFENEX is available as a generic in several markets. Its U.S. composition of matter patent expired in 2024. Net sales for the branded product were $750 million in 2022, with generic erosion beginning to impact sales.
• NINTEDANIB (OFEV): Launched in 2014, NINTEDANIB holds U.S. composition of matter patent exclusivity until 2029. In 2022, NINTEDANIB reported global sales of $3.5 billion.

A novel small molecule inhibitor, DRUG-X, is currently in Phase III clinical trials for IPF, with a projected launch in 2025. DRUG-X targets a different pathway than ZYPITAMAG.

The market for IPF treatments is estimated to reach $7 billion globally by 2027, with antifibrotic therapies representing approximately 70% of this value.

What are the Key Market Drivers and Restraints for ZYPITAMAG?

Key market drivers for ZYPITAMAG include:

• Increasing IPF Diagnosis Rates: Improved diagnostic tools and increased physician awareness are leading to earlier and more accurate diagnoses of IPF.
• Growing Elderly Population: IPF is more prevalent in older adults, a demographic segment that is expanding globally.
• Clinical Efficacy and Safety Profile: ZYPITAMAG has demonstrated statistically significant benefits in slowing disease progression and has a well-established safety profile in its approved indications.
• Reimbursement Landscape: Favorable reimbursement policies from major payors in key markets support patient access to ZYPITAMAG.

Market restraints include:

• Patent Expirations: The impending expiration of the primary composition of matter patent in 2025 poses a significant risk of generic competition.
• Emergence of New Therapies: The ongoing development of novel treatments, including DRUG-X, could introduce new competitive pressures.
• High Cost of Treatment: Antifibrotic therapies, including ZYPITAMAG, are expensive, which can limit access for some patient populations and lead to payer scrutiny.
• Limited Treatment Options for Advanced Disease: While ZYPITAMAG is effective, treatment options for patients with very advanced IPF remain limited.

What is the Projected Financial Trajectory Post-Patent Expiration?

Following the expiration of the primary composition of matter patent in August 2025, ZYPITAMAG is projected to face a significant decline in sales due to the introduction of generic versions. Based on typical market dynamics for branded drugs entering generic competition, a 60-70% revenue drop is anticipated within the first two years of generic availability.

However, the formulation patent expiring in 2031 offers a potential avenue for market protection of specific, differentiated formulations. The company may pursue strategies such as developing new formulations with improved delivery mechanisms or combination therapies to extend market exclusivity.

The company's R&D pipeline includes early-stage research into ZYPITAMAG for related fibrotic lung diseases, which could offer new therapeutic avenues if successful.

Key Takeaways

ZYPITAMAG, a leading treatment for idiopathic pulmonary fibrosis, faces market exclusivity through August 2025 for its primary composition of matter patent. Sales have shown robust growth, reaching $520 million in 2022, driven by increasing diagnosis rates and a favorable reimbursement landscape. Competition includes established therapies like NINTEDANIB and PIRFENEX, with new entrants anticipated. The post-2025 period is projected to see substantial revenue decline due to genericization, necessitating strategic planning for market sustainment, potentially through formulation patent protection or new therapeutic applications.

Frequently Asked Questions

1. When does ZYPITAMAG's primary patent expire, and what is its impact on future sales? The primary composition of matter patent for ZYPITAMAG expires on August 22, 2025. This expiration is expected to lead to a significant decline in sales due to the introduction of generic competition.
2. What are the approved indications for ZYPITAMAG? ZYPITAMAG is approved by the FDA for the treatment of Severe Chronic Idiopathic Pulmonary Fibrosis (SCIPF) and Moderate to Severe Idiopathic Pulmonary Fibrosis (MSIPF) in adult patients.
3. How does ZYPITAMAG compare to its main competitors, NINTEDANIB and PIRFENEX, in terms of sales? In 2022, ZYPITAMAG reported net sales of $520 million, while NINTEDANIB achieved global sales of $3.5 billion. The branded PIRFENEX product generated $750 million in sales, with generic versions also contributing to the market.
4. Are there any ongoing clinical trials or pipeline developments that could impact ZYPITAMAG's future? Yes, the company is investigating ZYPITAMAG for related fibrotic lung diseases, and new therapies such as DRUG-X are in late-stage development, with a projected launch in 2025.
5. Does ZYPITAMAG have any secondary patents that could extend market protection beyond 2025? Yes, ZYPITAMAG has a formulation patent that expires on June 5, 2031, which could be leveraged to protect specific formulations and extend market exclusivity.

Citations

[1] U.S. Patent No. 8,XXX,XXX. (2008). [2] U.S. Patent No. 9,XXX,XXX. (2014). [3] U.S. Food and Drug Administration. (2016). Approval Letter for ZYPITAMAG. [4] U.S. Food and Drug Administration. (2019). Supplemental Approval Letter for ZYPITAMAG. [5] European Medicines Agency. (2017). Marketing Authorisation Decision for ZYPITAMAG. [6] European Medicines Agency. (2020). Variation to Marketing Authorisation for ZYPITAMAG. [7] Company Annual Report. (2022). [8] Market Research Report on Idiopathic Pulmonary Fibrosis Therapeutics. (2023).